Quetiapine in Nine Youths with Autistic Disorder

Findling, Robert L.; McNamara, Nora; Gracious, Barbara L.; O’Riordan, Mary Ann; Reed, Michael D.; Demeter, Christine; Blumer, Jeffrey L.

doi:10.1089/1044546041649129

Cited by 91 publications

(32 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only six adolescents completed the study, and only two of them were responders in the analysis of aggression. 51 In the two studies, the most common adverse events were drowsiness and weight gain, the reasons why three patients discontinued treatment.…”

Section: Risperidonementioning

confidence: 99%

“…Olanzapine Quetiapine Ziprasidone Aripiprazole Clozapine 43 (n = 6) 50 (n = 12) 52 (n = 5) 53 (n = 3) 56 (n = 12) 44 (n = 9) 51 (n = 32) 54 (n = 1) 57 CS/OL N = 3 -----(n = 80) 36 (n = 101) 38 (n = 79) 39 Conduct disorder CR/OL -N = 2 N = 2 ---(n = 16) 41 (n = 16) 47 (n = 23) 42 (n = 24)* 49 CS N = 2 ----(n = 118) 33 -(n = 10) 34 Mental retardation CR/OL ----+ (n = 18) + (n = 8) CS + (N = 1) ----- Table 4 for children and adolescents, despite the limitations discussed in the text. Except for clozapine, studies did not find differences in their potency, and choices should be based on their adverse events.…”

Section: Risperidonementioning

confidence: 99%

“…52 Data about quetiapine and aripiprazole are still too limited to provide a minimally consistent evaluation of their adverse events. [47][48][49][50][51]53,54 As clozapine has a specific profile of action and adverse events, and its efficacy in treating aggression has already been demonstrated, 15,55,64 it should become the focus of more detailed investigations. 13 …”

Section: Risperidonementioning

confidence: 99%

See 2 more Smart Citations

Atypical antipsychotics in the treatment of pathological aggression in children and adolescents: literature review and clinical recommendations

Teixeira

Jacintho

Celeri

et al. 2013

Trends Psychiatry Psychother.

View full text Add to dashboard Cite

Objective: To review the literature about the use of atypical antipsychotics in the treatment of pathological aggression in children and adolescents. Method: The databases MEDLINE, SciELO, and LILACS were searched for publications in Portuguese or English from 1992 to August 2011 using the following keywords: mental disease, child, adolescent, treatment, atypical antipsychotic, aggressive behavior, aggression, and violent behavior. Results: Sixty-seven studies of good methodological quality and clinical interest and relevance were identified. Studies including children and adolescents were relatively limited, because few atypical antipsychotics have been approved by the Food and Drug Administration (FDA). All the medications included in this review (risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole and clozapine) have some effectiveness in treating aggression in children and adolescents, and choices should be based on clinical indications and side effects. Conclusions: There are few studies about the effectiveness and safety of atypical antipsychotics for the pediatric population, and further randomized controlled studies with larger groups of patients and more diagnostic categories, such as severe conduct disorder and oppositional defiant disorder, should be conducted to confirm the results reported up to date and to evaluate the impact of long-term use. Keywords: Aggression, violence, atypical antipsychotics, behavioral disorders, children, adolescents. ResumoObjetivo: Realizar uma revisão sistemática da literatura científica sobre o uso de antipsicóticos atípicos (APAs) no tratamento da agressividade patológica em crianças e adolescentes. Método: Foi realizada busca eletrônica nas bases de dados MEDLINE, SciELO e LILACS, de 1992 a agosto 2011, considerando artigos publicados em língua inglesa e portuguesa. Foram utilizadas associações das seguintes expressões: mental disease, child, adolescent, treatment, atypical antipsychotic, aggressive behaviour, aggression e violent behavior. Resultados: Foram identificados 67 artigos de boa qualidade metodológica, de relevância e interesse clínico para o tema em foco. De modo geral, os estudos são relativamente limitados para esta faixa etária, resultado do fato de poucos APAs terem sido aprovados pela Food and Drug Administration (FDA). Dentre as medicações consideradas nesta revisão (risperidona, olanzapina, quetiapina, ziprazidona, aripiprazol e clozapina), todas elas podem ter alguma efetividade no tratamento da agressividade em crianças e adolescentes, ficando a escolha baseada na indicação clínica e perfil de efeitos colaterais. Conclusão: O número ainda limitado de estudos acerca da efetividade e segurança na população pediátrica demanda pesquisas futuras com grupos maiores de pacientes e com mais categorias diagnósticas (como, por exemplo, as formas graves de transtorno de conduta e transtorno desafiador de oposição), desenhadas de forma randomizada e controlada. Assim poderão ser confirmados os achados até o momento e o impacto do uso em lo...

show abstract

Section: Risperidonementioning

confidence: 99%

Section: Risperidonementioning

confidence: 99%

Section: Risperidonementioning

confidence: 99%

See 1 more Smart Citation

Atypical antipsychotics in the treatment of pathological aggression in children and adolescents: literature review and clinical recommendations

Teixeira

Jacintho

Celeri

et al. 2013

Trends Psychiatry Psychother.

View full text Add to dashboard Cite

show abstract

“…Another open-label trial of quetiapine in PDD enrolled 9 adolescents (aged 12-17 years) with autism (76). Subjects were treated with quetiapine (mean dose, 292 mg/d) for 12 weeks.…”

Section: Atypical Antipsychotics In Autismmentioning

confidence: 99%

Antipsychotics in the treatment of autism

Posey¹,

Stigler²,

Erickson³

et al. 2008

J. Clin. Invest.

171

104

View full text Add to dashboard Cite

Atypical antipsychotics have become indispensable in the treatment of a variety of symptoms in autism. They are frequently used to treat irritability and associated behaviors including aggression and self injury. They may also be efficacious for hyperactivity and stereotyped behavior. This review presents the rationale for the use of this drug class in autism and reviews the most important studies published on this topic to date. Significant adverse effects, including weight gain and the possibility of tardive dyskinesia, are reviewed. Future research directions are discussed.

show abstract

“…Encouraging open-label studies of risperidone, olanzapine, and ziprasidone, as well as relatively negative studies of quetiapine have been published for PDDs (Findling et al1999;Potenza et al 1999;Malone et al 2001;Masi et al 2001;McDougle et al 2002;Corson et al 2004;Findling et al 2004;Hardan et al 2005;Malone et al 2007).…”

mentioning

confidence: 99%